NCCN® Guidelines now include IsoPSA to further define the probability of high-grade prostate cancerCLEVELAND (BUSINESS WIRE) Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer t.
Posted on 196
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has closed a Series D round of $17.4 million. The round was led by LYFE Capital, with participation from existing investors including Cleveland Clinic and others. Following the close of the round, the company received a term sheet for a $2M convertible note, expected to close shortly. Funds raised will be used to expand commercialization of IsoPSA the company’s first diagnostic test, designed to enhance early detection of prostate cancer as well as to expand internal infrastructure and operations to support platform development for other tests, including breast and lung cancer.